## Conclusions and levels of evidence for metabolic syndrome surveillance for CAYA cancer survivors

Who needs surveillance?	
Risk of MetS <sup>a</sup> in CAYA cancer survivors	GRADE level of evidence
Increased risk of MetS in CAYA cancer survivors vs the normal population	⊕⊕⊖ LOW <sup>(24-34)</sup>
Unknown risk of MetS related mortality in CAYA cancer survivors vs the	No studies
normal population	
Increased risk after C(S)RT vs no C(S)RT	⊕⊕⊕ MODERATE (26, 29-31, 35-37, 39)
Unknown risk after radiotherapy to the HP axis	No studies
No significant effect of abdominal radiation vs no abdominal radiation	⊕⊕⊖ LOW <sup>(29)</sup>
No significant effect of chest radiation vs no radiation	⊕⊕⊖ LOW <sup>(29)</sup>
Unknown risk after higher doses of radiotherapy vs lower doses	No studies
Increased risk after a combination of HSCT and TBI vs no HSCT	⊕⊕⊕⊖ MODERATE <sup>(29)</sup> 31, 35, 37, 38)
No significant effect of HSCT without TBI vs chemo-only and age/sex- matched controls	⊕⊕⊖ LOW (31, 37)
No significant effect of MetS after platinum agents	⊕⊕⊖⊖ LOW <sup>(29)</sup>
No significant effect of anthracyclines vs no anthracyclines	⊕⊕⊕ MODERATE (29, 30)
No significant effect of anthracycline dose	⊕⊕⊖ LOW <sup>(29, 30)</sup>
Increased risk after oral methotrexate vs no oral methotrexate	⊕⊕⊖ LOW <sup>(30)</sup>
No significant effect of steroids	⊕⊕⊕⊖ MODERATE (30),
Unknown risk after surgery	No studies
Increased risk in males vs females	⊕⊖⊖ VERY LOW <sup>(29,</sup> <sub>37-39)</sub>
No significant effect of age at diagnosis or HSCT	⊕⊕⊖ LOW <sup>(29, 38)</sup>
Increased risk in testicular cancer survivors with lower but not necessarily abnormal total testosterone levels	⊕⊕⊖ LOW (41, 42)
Unknown risk in survivors with thyroid hormone deficiency or excess	No studies
Increased risk in survivors with GH insufficiency vs without GH insufficiency	⊕⊕⊖ LOW <sup>(26)</sup>
Unknown risk in survivors treated with hormonal replacement therapy	No studies
No significant effect of former/current smoking vs never smoking	⊕⊕⊖ LOW <sup>(29)</sup>
Increased risk in survivors who have a sedentary lifestyle vs no sedentary lifestyle	⊕⊕⊖ LOW <sup>(29, 43)</sup>
Increased risk in survivors who have a diet that does not resemble a Mediterranean diet vs a diet that highly resembles a Mediterranean diet	⊕⊕⊖⊖ LOW (43)
Increased risk in survivors that do not adhere to diet and physical activity guidelines vs survivors that adhere to diet and physical activity guidelines	⊕⊕⊖⊖ LOW <sup>(36)</sup>
Increased risk in survivors with a higher BMI vs lower BMI at primary cancer diagnosis	⊕⊕⊕⊕ HIGH (38-40)
Which surveillance modality should be used?	
Diagnostic tests to detect MetS in CAYA cancer survivors	GRADE level of evidence
Overweight or obesity: BMI and waist circumference	Existing guidelines (14-16, 20
Hypertension: blood pressure using a blood pressure monitor	Existing guidelines (14-16, 2)

(pre)diabetes: fasting blood glucose	Existing guidelines (14-16, 20, 51)	
Dyslipidemia: fasting lipid profile	Existing guidelines (14-16, 20, 51)	
When should surveillance be initiated?		
Latency time of MetS in CAYA cancer survivors	GRADE level of evidence	
Unknown latency time of developing MetS	No studies	
At what frequency should surveillance be performed?		
Risk of MetS over time in CAYA cancer survivors	GRADE level of evidence	
The cumulative incidence of MetS increases over time	⊕⊕⊕ HIGH (26, 31, 39)	
What should be done if abnormalities are identified?		
Risk of MetS after lifestyle interventions	GRADE level of evidence	
Unknown risk in survivors after lifestyle interventions	No studies	

Abbreviations: MetS = metabolic syndrome, CAYA = childhood, adolescent and young adult, C(S)RT = cranial or craniospinal radiotherapy, HP = hypothalamic pituitary, TBI = total body irradiation, HSCT = hematological stem cell transplantation, GH = growth hormone, BMI = body mass index, LTFU = long-term follow-up.

<sup>&</sup>lt;sup>a</sup> The clustering of at least 3 cardiovascular risk factors. Definitions of MetS were as described in each eligible study.